Athira Pharma has marked a significant milestone by acquiring global development and commercialization rights to lasofoxifene, a promising Phase 3 breast cancer drug targeting ESR1 mutations. This news sent the biotech company’s stock soaring by an impressive 73.4% in premarket trading.
Understanding Lasofoxifene and the ESR1 Mutation
Lasofoxifene, a selective estrogen receptor modulator (SERM), is focused on treating patients with metastatic breast cancer who have ESR1 mutations. These mutations often develop after standard treatments fail, leaving patients with limited options. ESR1 mutations affect approximately 40% of breast cancer patients, highlighting the immense potential of this treatment.
The ongoing ELAINE-3 Phase 3 clinical trial, expected to conclude in mid-2027, has already reached significant enrollment milestones. Encouraging data from the earlier ELAINE-2 trial showed a progression-free survival of 13 months in heavily pre-treated patients, providing strong optimism for lasofoxifene’s future impact.
Financial Backing and Strategic Goals
Athira Pharma strengthened its financial position with a $90 million private placement led by key investors like Commodore Capital, Perceptive Advisors, and TCGX. This deal, which includes common stock and pre-funded warrants, paves the way for up to $146 million in additional funding if all warrants are exercised, extending the company’s funding runway into 2028.
Licensing and Payment Structure
The acquisition consists of an exclusive license from Sermonix Pharmaceuticals, which includes milestone payments of up to $100 million and single-digit royalties tied to commercialization. Athira also secured manufacturing and related rights from Ligand Pharmaceuticals, with up to $21 million in additional product milestone obligations.
Expanding the Oncology Pipeline
With its pivot into oncology, Athira Pharma is not only focused on developing lasofoxifene but also advancing its ALS (amyotrophic lateral sclerosis) treatment, ATH-1105. According to CEO Mark Litton, “This agreement for the rights to the Phase 3 lasofoxifene program for metastatic breast cancer is a step in building a pipeline with the potential to change lives and create enduring value.”
Related Resource: Empowering Breast Cancer Skincare
Alongside cutting-edge treatments like lasofoxifene, breast cancer patients often face specific skincare challenges due to treatments. Products such as CeraVe Moisturizing Cream are dermatologist-recommended to soothe and restore skin during and post-treatment. Its ingredients, including ceramides and hyaluronic acid, provide a gentle yet effective solution for sensitive skin.
Looking Ahead
Athira Pharma’s strategic vision and financial planning are set to redefine its niche as a biotech pioneer in oncology. With promising trials and robust backing, the company is on track to deliver breakthroughs for patients and create lasting value for shareholders.